Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, February 27th. Analysts expect Nautilus Biotechnology to post earnings of ($0.16) per share for the quarter. Investors that are interested in participating in the company's conference call can do so using this link.
Nautilus Biotechnology Stock Down 3.8 %
Shares of NASDAQ NAUT traded down $0.06 on Friday, hitting $1.54. The company had a trading volume of 79,725 shares, compared to its average volume of 91,644. Nautilus Biotechnology has a 12-month low of $1.53 and a 12-month high of $3.09. The firm has a market capitalization of $193.36 million, a P/E ratio of -2.75 and a beta of 1.21. The business has a 50 day moving average of $1.77 and a two-hundred day moving average of $2.28.
Institutional Trading of Nautilus Biotechnology
An institutional investor recently raised its position in Nautilus Biotechnology stock. Bank of America Corp DE raised its holdings in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Free Report) by 37.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 49,419 shares of the company's stock after purchasing an additional 13,363 shares during the quarter. Bank of America Corp DE's holdings in Nautilus Biotechnology were worth $83,000 at the end of the most recent quarter. Institutional investors own 50.71% of the company's stock.
Analyst Upgrades and Downgrades
Separately, The Goldman Sachs Group downgraded shares of Nautilus Biotechnology from a "neutral" rating to a "sell" rating and lowered their price objective for the company from $2.25 to $1.75 in a research report on Thursday, December 5th.
Check Out Our Latest Report on Nautilus Biotechnology
About Nautilus Biotechnology
(
Get Free Report)
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
Read More
Before you consider Nautilus Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nautilus Biotechnology wasn't on the list.
While Nautilus Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
